*Tentative Schedule as of August, 2025
Plenary Lecture
Masaru Ishii (The University of Osaka)
Date : Dec 9 (Tue) 8:45-9:25(tentative)
Shuichi Yamamoto (Yamaguchi University)
Date : Dec 10 (Wed) 9:00-9:40 (tentative)
ESACT Plenary Lecture
E. Terry Papoutsakis (University of Delaware)
Antonio Roldao (iBET)
Antonio Roldao (iBET)
Date : Dec 9 (Tue)14:20-15:20 (tentative)
Symposium
S1 Recent advances in alternatives to animal testing
Date : Dec 8 (Mon)13:15-15:15 (tentative)
Organizer : Yoshinori Katakura (Kyushu University)
Hiroko Isoda (Tsukuba University)
Hiroko Isoda (Tsukuba University)
Tamihide Matsunaga (Nagoya City University)
Seiichi Ishida (Sojo University)
Hiroyuki Mizuguchi (The University of Osaka)
This symposium has been organized with the aim of providing information on topics related to food and health. We will introduce new initiatives, including alternative methods to animal testing for safety and functional evaluations of foods and pharmaceuticals. In particular, we request presentations on examples of functional testing systems for foods and pharmaceuticals using iPS cells and organoid-derived intestinal and liver cells, as well as new approaches to safety evaluations.
S2 Future of cell manufacutruing
Date : Dec 8 (Mon) 15:30-17:30 (tentative)
Organizer : Masahiro Kino-oka( The University of Osaka)
Ryuji Kato(Nagoya University)
Ryuji Kato(Nagoya University)
Jongyoon Han (Massachusetts Institute of Technology Department of Biological Engineering)
Ryuji Kato (Nagoya University)
Mee-Hae Kim (The University of Osaka)
Masayoshi Tsukahara (CiRA Foundation)
Masahiro Kino-oka (The University of Osaka)
This symposium will introduce technologies that contribute to the manufacture of cell processing products for regenerative medicine and cell therapy. In particular, The symposium will promote understanding by presenting the latest technologies related to process control, quality control, QbD, manufacturing stability, prediction, and efforts toward actual manufacturing, and will hold discussions that lead to future prospects.
S3 Digital & Data Share for Cell / Cell Culture Engineering
Date : Dec 9 (Tue) 9:35-11:35 (tentative)
Organizer : Takeshi Omasa (The University of Osaka)
Dong-Yup Lee (Sungkyunkwan University)
Yu Tsunoda (The University of Osaka)
Hirotaka Kuroda(Shimadzu Corporation)
Keisuke Shibuya (Hitachi, Ltd.)
Digitalization and data sharing are becoming increasingly important in cell/cell culture engineering. This symposium will focus on genome-scale modeling, omics analysis, and international collaborative research, and will discuss recent results and the current state of international collaboration.
S4 Bioproduction – Cutting-edge technologies for acceleration of development
Date : Dec 9 (Tue) 16:40-18:40 (tentative)
Organizer : Yasuhiro Takagi(Astellas Pharma)
Tomohiro Doi(SHIONOGI)
Tomohiro Doi(SHIONOGI)
Christina Alves (Takeda Pharmaceuticals)
Tsuyoshi Yamaguchi (Kyowa-Kirin)
Kenta Komura (CHUGAI PHARMACEUTICAL)
Sherry Gu (Wuxi Biologics)
Recent advances in cell line development have significantly accelerated biologics manufacturing. This symposium will highlight innovative technologies and strategies in cell line development aimed at enhancing stability, productivity, product quality, and process robustness, as well as shortening timelines for drug development. Experts will present state-of-the-art technologies, case studies, and future perspectives, providing attendees with valuable insights into overcoming current challenges and exploring new opportunities in cell line development and its applications.
S5 Bioproduction – New technology for cell culture and purification
Date : Dec 10 (Wed) 9:50-11:50 (tentative)
Organizer : Masayoshi Onitsuka(Tokushima Univ.)
Yoshinori Kawabe(Kyushu Univ.)
Yoshinori Kawabe(Kyushu Univ.)
Emmanuel Anane (FUJIFILM Diosynth Biotechnologies)
Ryuma Nagano (Kyowa-Kirin)
Masato Hoshino (Daiichi Sankyo)
Sumiko Hasegawa (Takeda Pharmaceutical Company)
Recent advances in upstream and downstream processes have greatly improved the efficiency and reliability of biologics manufacturing. This symposium will highlight innovative technologies and strategies in cell culture optimization, process intensification, and novel purification methods to enhance yield, consistency, and cost-effectiveness. Experts will present state-of-the-art technologies, case studies, and future perspectives, providing attendees with valuable insights into addressing current challenges and driving further progress in culture and purification process development.
S6 Current situation and perspective of rAAV manufacturing and quality control for gene therapy
Date : Dec 11 (Thu) 9:00-11:00 (tentative)
Organizer : Susumu Uchiyama(The University of Osaka)
Yugo Hirai(Chitose Laboratory Corp.)
Susumu Uchiyama (The University of Osaka)
Yugo Hirai (Chitose Laboratory Corp.,)
Kasuhisa Uchida (Kobe University)
TBA
Recombinant adeno-associated virus (rAAV) has emerged as a leading platform for in vivo gene therapy, with several products already approved and more than 200 candidates currently in development. Nevertheless, significant challenges remain, particularly in the manufacturing and quality control of this complex and novel modality. This symposium will highlight recent advances in rAAV CMC, including innovations in cell platforms, analytics, and clinical translation, and provide a forum to discuss future perspectives in the field.